FDA Adds Boxed Warning for Symptomatic Hypophosphatemia With Ferric Carboxymaltose
Episode Summary
FDA added a boxed warning for ferric carboxymaltose due to severe, prolonged hypophosphatemia, emphasizing patient risk assessment, symptom education, phosphate correction, and monitoring.